Business Context and Reporting Period
This Form 8-K Current Report, dated January 16, 2007, details two material events for IRIDEX Corporation: the entry into a significant credit facility and the completion of an asset acquisition. The reporting period covers events occurring on January 16, 2007, with a press release issued on January 17, 2007.
Key Financial Metrics and Obligations
- Debt Financing: IRIDEX secured a Credit Agreement with Mid-Peninsula Bank and the Export-Import Bank of the United States (Exim Bank).
- Term Loan: $6 million borrowed in full on January 16, 2007. Repayment is scheduled in 60 monthly installments from February 28, 2007, to February 28, 2012.
- Revolving Line of Credit: Up to $6 million, secured by eligible domestic accounts (80% borrowing base). Maturity date is January 31, 2009.
- Exim Sublimit: Up to $3 million of the revolving line is guaranteed by Exim Bank, based on eligible foreign accounts and inventory. Subject to a $45,000 annual facility fee.
- Interest Rate: Prime rate (Wall Street Journal) minus 0.5%, subject to adjustments for defaults or late payments.
- Acquisition Consideration: IRIDEX acquired the aesthetics business of Laserscope for a total consideration of $28 million at closing.
- Cash Payment: $26 million in immediately available funds.
- Stock Payment: 213,435 shares of IRIDEX common stock.
- Contingent Payment: Up to an additional $9 million based on the book value of specific inventory following a 6-9 month manufacturing transition period.
- Liquidity Covenant: The company must maintain $3 million in unrestricted cash in an account with the Lender.
Material Changes and Transactions
The filing reports the completion of the acquisition of Laserscope's aesthetics business, including equipment, inventory, contracts, intellectual property, and equity interests in Laserscope's UK and French subsidiaries. This transaction was funded in part by the new $6 million term loan. The acquisition expands IRIDEX's product portfolio into the aesthetics market.
Outlook, Risks, and Covenants
- Financial Covenants: The credit agreements require IRIDEX to maintain profitability during certain periods and meet specific tangible net worth and debt service requirements.
- Restrictive Covenants: The agreements limit the company's ability to incur additional indebtedness, create liens, merge, dispose of assets, make investments, or pay dividends without lender consent.
- Events of Default: Includes payment defaults, covenant breaches, cross-defaults, bankruptcy, and material adverse changes. An event of default triggers a 4.5% interest rate increase and potential acceleration of all obligations.
- Security Interest: Obligations are secured by a lien on substantially all of the Company's assets.
Key Facts for Investor Verification
- Verify the immediate impact of the $26 million cash outflow on the company's current liquidity position.
- Confirm the valuation of the 213,435 shares issued as part of the acquisition consideration.
- Monitor the company's ability to meet the $3 million unrestricted cash covenant and profitability requirements.
- Assess the potential liability of the up to $9 million contingent payment based on inventory book value.
- Review the integration risks associated with the Laserscope aesthetics business and the 6-9 month transition period.